Fox Run Management L.L.C. Takes $448,000 Position in Cencora, Inc. $COR

Fox Run Management L.L.C. acquired a new stake in Cencora, Inc. (NYSE:COR) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 1,495 shares of the company’s stock, valued at approximately $448,000.

Several other hedge funds have also recently bought and sold shares of the stock. Atlantic Edge Private Wealth Management LLC boosted its holdings in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares during the period. Obermeyer Wealth Partners boosted its stake in Cencora by 1.3% in the 1st quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock worth $758,000 after purchasing an additional 36 shares during the period. Grove Bank & Trust increased its holdings in Cencora by 4.3% during the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company’s stock worth $264,000 after purchasing an additional 36 shares in the last quarter. U.S. Capital Wealth Advisors LLC raised its stake in shares of Cencora by 0.4% in the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock valued at $2,563,000 after purchasing an additional 38 shares during the period. Finally, Monument Capital Management lifted its holdings in shares of Cencora by 2.4% in the second quarter. Monument Capital Management now owns 1,637 shares of the company’s stock valued at $491,000 after purchasing an additional 38 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. The trade was a 11.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This represents a 9.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 41,544 shares of company stock worth $12,230,941 in the last 90 days. Corporate insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on COR. JPMorgan Chase & Co. increased their price objective on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday. Wells Fargo & Company raised their price target on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a report on Saturday. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and a consensus price target of $371.09.

Cencora Stock Performance

NYSE COR opened at $365.26 on Wednesday. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The firm’s fifty day moving average price is $317.14 and its two-hundred day moving average price is $300.68. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $366.17. The firm has a market capitalization of $70.82 billion, a P/E ratio of 37.58, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The company had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the firm posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. Cencora’s dividend payout ratio (DPR) is presently 30.19%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.